Irv Arons

Irv Arons’ Journal is a well-read blog that reports on new drugs and devices for the treatment of retinal diseases, including age-related macular degeneration (AMD). Until his retirement, Irv was a consultant to the ophthalmic and medical laser industries, working for management consultants Arthur D. Little for 25 years and running his own company, Spectrum Consulting, for 11 years.

Content by Irv Arons:

Business & Profession Basic & Translational Research

Gene Editing: The Next Frontier in Ophthalmology

01/15/2016 | Irv Arons

Imagine being able to edit, delete or replace defective genes. It’s happening in research labs, and will soon head to the clinic

Subspecialties Retina

The Optogenetic Option

11/06/2015 | Irv Arons

Optogenetics holds the potential of reversing blindness in retinal disease – but how far has the field come, and who are the key players?

Subspecialties Health Economics and Policy

The Economics of Gene Therapy

05/11/2015 | Irv Arons

Gene and stem cell therapies hold the promise of restoring vision in patients with retinal diseases – but who should be paying for these treatments, and how?

Subspecialties Retina

Regenerating the Retina

02/10/2015 | Irv Arons

Retinal progenitor cell transplantation offers a new approach to repairing damaged photoreceptors

Business & Profession Basic & Translational Research

Gene Therapy Clinical Trials

01/21/2014 | Irv Arons, Mark Hillen

The EMA approved the first gene therapy agent in 2012 – for lipoprotein lipase deficiency. Might gene therapies for ophthalmic disease reach the wards any time soon?

Business & Profession Basic & Translational Research

Stem Cell Clinical Trials

12/03/2013 | Irv Arons, Mark Hillen

Therapies based on stem cell treatments are considered to have tremendous potential in medicine.